Olema Pharmaceuticals Leases New South San Francisco HQ

Why It Matters

The deal secures premium biotech office space for Olema, supporting its growth while reinforcing South San Francisco’s emergence as a life‑science hub. It also highlights sustained demand for high‑quality, purpose‑built campuses in a competitive Bay Area market.

Key Takeaways

• Olema leases 38,000 SF HQ in South San Francisco.
• Lease spans seven years with five‑year extension option.
• Initial 25,000 SF expansion costs $12.3 M in base rent.
• Additional 13,100 SF future phase adds $6.1 M rent.
• Kilroy Oyster Point development includes 865,000 SF of office space.

Pulse Analysis

Olema Pharmaceuticals' decision to relocate its corporate headquarters to South San Francisco reflects a broader trend of biotech firms gravitating toward purpose‑built campuses that blend laboratory capacity with collaborative office environments. The 38,000 square‑foot lease at Kilroy Oyster Point places the company adjacent to a growing ecosystem that includes the University of California, San Francisco's pharmacy and clinical laboratory hub, as well as other life‑science tenants such as Acadia Pharmaceuticals. Proximity to this cluster offers Olema easier access to talent pipelines, research partners, and shared services that can accelerate drug‑development timelines.

The lease, structured for seven years with a five‑year renewal option, commits Olema to $12.3 million in base rent for the initial 25,000 square‑foot expansion and an additional $6.1 million for a future 13,100‑square‑foot phase. Kilroy Realty, the landlord, will finish tenant improvements by mid‑September, positioning the space for immediate occupancy. Kilroy's Oyster Point Phase 2 adds 865,000 square feet of office and amenity space—including an open‑air amphitheater and food‑and‑beverage hub—making the site a premium address for high‑growth companies seeking flexible, upscale environments.

From a market perspective, Olema's move underscores the increasing demand for premium biotech real estate on the Bay Area’s south‑side, a region that balances lower costs than downtown San Francisco with strong transportation links and a deep talent pool. The transaction bolsters Kilroy's occupancy metrics and signals confidence in the long‑term viability of life‑science campuses despite broader economic headwinds. As more companies secure multi‑year leases, the area is likely to see heightened investment in supporting infrastructure, further cementing South San Francisco’s role as a biotech hub.